| abstract |
The compounds of formula (I) or salts, prodrugs or solvates thereof are disclosed. Uses thereof as GLK activators, pharmaceutical compositions containing them, and methods of making the same are also disclosed.n n n Formula In n n n n n n n In the above formula, R 1 is methoxymethyl; R 2 is selected from —C (O) NR 4 R 5 , —SO 2 NR 4 R 5 , —S (O) p R 4 and HET-2; HET-1 is a 5 or 6 membered optionally substituted with a C-linked heteroaryl ring; HET-2 is a 4, 5 or 6 membered C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is for example selected from hydrogen, optionally substituted (1-4C) alkyl and HET-2; R 5 is hydrogen or (1-4C) alkyl; Or R 4 and R 5 together with the nitrogen atom attached to them may form a heterocyclyl ring system as defined by HET-3; HET-3 is, for example, an optionally substituted N-linked 4, 5 or 6 membered saturated or partially unsaturated heterocyclyl ring; p is 0, 1 or 2 (in each case independently); m is 0 or 1; n is 0, 1 or 2; However, when m is 0, n is 1 or 2. |